T
Tectonic Therapeutic, Inc. (TECX)
NGM – Real Time Price. Currency in USD
27.96
+0.44 (1.60%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
27.96
+0.44 (1.60%)
At close: May 12, 2026, 4:00 PM EDT
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
| Name | Position |
|---|---|
| Dr. Alise S. Reicin M.D., Ph.D. | President, CEO, Secretary & Director |
| Dr. Marc Schwabish Ph.D. | Chief Business Officer |
| Dr. Marcella Kuhlman Ruddy M.D., M.S. | Chief Medical Officer |
| Dr. Peter McNamara Ph.D. | Chief Scientific Officer |
| John Diener | Senior Vice President of Antibody Engineering & Protein Sciences |
| Mr. Anthony Muslin M.D. | Chief Development Officer |
| Mr. Daniel Lochner M.B.A. | Chief Financial Officer |
| Ms. Geraldine Peters-Wiles | Senior Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 10-Q | tecx-20260331.htm |
| 2026-04-24 | DEFA14A | d99019ddefa14a.htm |
| 2026-04-24 | DEF 14A | d54807ddef14a.htm |
| 2026-04-23 | 8-K | d150495d8k.htm |
| 2026-03-09 | S-8 POS | d119719ds8pos.htm |
| 2026-02-27 | S-8 | d119719ds8.htm |
| 2026-02-26 | 8-K | tecx-20260226.htm |
| 2026-02-24 | 8-K | d50095d8k.htm |
| 2025-11-06 | 10-Q | tecx-20250930.htm |
| 2025-10-30 | 8-K | d30823d8k.htm |